JP2024520630A - ブルトン型チロシンキナーゼの阻害剤及びその使用方法 - Google Patents
ブルトン型チロシンキナーゼの阻害剤及びその使用方法 Download PDFInfo
- Publication number
- JP2024520630A JP2024520630A JP2023574315A JP2023574315A JP2024520630A JP 2024520630 A JP2024520630 A JP 2024520630A JP 2023574315 A JP2023574315 A JP 2023574315A JP 2023574315 A JP2023574315 A JP 2023574315A JP 2024520630 A JP2024520630 A JP 2024520630A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- iii
- alkyl
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196843P | 2021-06-04 | 2021-06-04 | |
| US63/196,843 | 2021-06-04 | ||
| PCT/IB2022/055154 WO2022254371A1 (en) | 2021-06-04 | 2022-06-02 | Inhibitors of bruton's tyrosine kinase and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520630A true JP2024520630A (ja) | 2024-05-24 |
| JPWO2022254371A5 JPWO2022254371A5 (https=) | 2025-05-28 |
| JP2024520630A5 JP2024520630A5 (https=) | 2025-05-28 |
Family
ID=82214195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574315A Pending JP2024520630A (ja) | 2021-06-04 | 2022-06-02 | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230013755A1 (https=) |
| EP (1) | EP4346834A1 (https=) |
| JP (1) | JP2024520630A (https=) |
| KR (1) | KR20240019214A (https=) |
| CN (1) | CN117412753A (https=) |
| AU (1) | AU2022284369A1 (https=) |
| BR (1) | BR112023025459A2 (https=) |
| CA (1) | CA3220015A1 (https=) |
| CL (2) | CL2023003564A1 (https=) |
| IL (1) | IL308951A (https=) |
| JO (1) | JOP20230310A1 (https=) |
| MX (1) | MX2023014435A (https=) |
| TW (1) | TW202317127A (https=) |
| WO (1) | WO2022254371A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964976B1 (en) | 2023-09-12 | 2024-04-23 | King Faisal University | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors |
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015008042A2 (pt) | 2012-10-11 | 2017-07-04 | Pharmacyclics Inc | diagnósticos complementares para terapia com inibidor de quinase da família tec |
| MA40596B1 (fr) * | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2022
- 2022-06-02 AU AU2022284369A patent/AU2022284369A1/en active Pending
- 2022-06-02 MX MX2023014435A patent/MX2023014435A/es unknown
- 2022-06-02 IL IL308951A patent/IL308951A/en unknown
- 2022-06-02 JP JP2023574315A patent/JP2024520630A/ja active Pending
- 2022-06-02 CN CN202280039736.2A patent/CN117412753A/zh active Pending
- 2022-06-02 BR BR112023025459A patent/BR112023025459A2/pt unknown
- 2022-06-02 EP EP22733732.6A patent/EP4346834A1/en active Pending
- 2022-06-02 CA CA3220015A patent/CA3220015A1/en active Pending
- 2022-06-02 US US17/830,714 patent/US20230013755A1/en active Pending
- 2022-06-02 WO PCT/IB2022/055154 patent/WO2022254371A1/en not_active Ceased
- 2022-06-02 TW TW111120615A patent/TW202317127A/zh unknown
- 2022-06-02 KR KR1020247000043A patent/KR20240019214A/ko active Pending
-
2023
- 2023-11-29 CL CL2023003564A patent/CL2023003564A1/es unknown
- 2023-11-29 JO JOJO/P/2023/0310A patent/JOP20230310A1/ar unknown
-
2024
- 2024-09-26 CL CL2024002895A patent/CL2024002895A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022284369A1 (en) | 2024-01-25 |
| IL308951A (en) | 2024-01-01 |
| EP4346834A1 (en) | 2024-04-10 |
| BR112023025459A2 (pt) | 2024-02-27 |
| CL2024002895A1 (es) | 2025-02-14 |
| CA3220015A1 (en) | 2022-12-08 |
| CN117412753A (zh) | 2024-01-16 |
| CL2023003564A1 (es) | 2024-06-21 |
| TW202317127A (zh) | 2023-05-01 |
| KR20240019214A (ko) | 2024-02-14 |
| WO2022254371A1 (en) | 2022-12-08 |
| US20230013755A1 (en) | 2023-01-19 |
| JOP20230310A1 (ar) | 2023-11-29 |
| MX2023014435A (es) | 2024-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021240244B2 (en) | Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor | |
| US20230013755A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| US20160022683A1 (en) | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors | |
| US20240238291A1 (en) | Combinations for treatment of cancer | |
| US12564590B2 (en) | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | |
| CN108024996A (zh) | 布鲁顿氏酪氨酸激酶抑制剂组合和其用途 | |
| CA3223610A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| EA051432B1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| HK40107411A (zh) | 布鲁顿氏酪氨酸激酶抑制剂及其使用方法 | |
| HK40107203A (en) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor | |
| HK1249015B (en) | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250520 |